Prevalence of neuromyelitis optica spectrum disorder in the United States

Abstract

Background:

Neuromyelitis optic spectrum disorder (NMOSD) is a rare demyelinating, autoimmune disease and the burden in United States is not well characterized.

Objective:

The objective of this study was to determine the 2022 US prevalence of NMOSD.

Methods:

We constructed a cross-sectional study using aggregated electronic health record data for 25.7 million patients who had a 2022 clinical encounter. The data originated from the TriNetX US Collaborative Network of 55 healthcare organizations that span all 50 states. NMOSD prevalence was determined by querying for age-interval, sex, and race combinations, with direct standardization to the 2022 US Census data.

Results:

There were 1772 NMOSD patients among 25,743,039 patients for a prevalence of 6.88/100,000. Prevalence was the highest in Blacks (12.99/100,000) who represented 27.7% of NMOSD patients, then Asians (9.41/100,000and Whites (5.58/100,000). Among females, the prevalence of NMOSD was 9.48/100,000, and Black and Asian females had a 2.65- and 1.94-times higher prevalence than White females. In males, the prevalence of NMOSD was 3.52/100,000 and it did not differ by race. We observed a 3/5:1 female-to-male ratio in NMOSD. The age- and sex-adjusted 2022 estimate of persons with NMOSD in the United States was 15,413 females and 6233 males.

Conclusion:

We estimate that there were near 22,000 Americans living with NMOSD in 2022.

Keywords

Neuromyelitis optica spectrum disorder NMOSD prevalence epidemiology

Get full access to this article

View all access options for this article.

References

Wingerchuk

Lennon

Lucchinetti

, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6(9): 805–815.

Jarius

Aktas

Ayzenberg

, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)—Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol 2023; 270(7): 3341–3368.

Beekman

Keisler

Pedraza

, et al. Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm 2019; 6(4): e580.

Bruckner-Tuderman

. Epidemiology of rare diseases is important. J Eur Acad Dermatol Venereol 2021; 35(4): 783–784.

Hor

Asgari

Nakashima

, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 2020; 11: 501.

Musubire

Derdelinckx

Reynders

, et al. Neuromyelitis optica spectrum disorders in Africa: A systematic review. Neurol Neuroimmunol Neuroinflamm 2021; 8(6): e1089.

Flanagan

Cabre

Weinshenker

, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016; 79(5): 775–783.

Exuzides

Sheinson

, et al. Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database. J Med Econ 2021; 24(1): 581–588.

GBD 2017 US Neurological Disorders Collaborators, Feigin

Vos

, et al. Burden of neurological disorders across the US from 1990–2017: A global burden of disease study. JAMA Neurol 2021; 78(2): 165–176.

10.

Harel

Gorman

Wallin

. New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: A systematic review. Front Neurol 2023; 14: 1099758.

11.

Taquet

Sillett

Zhu

, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 2022; 9(10): 815–827.

12.

Wang

, et al. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. Eclinicalmedicine 2022; 53: 101619.

13.

Singh

Khan

. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: A multicenter research network study. Gastroenterology 2020; 159(2): 768–771.

14.

Kendall

Olaker

Kaelber

, et al. Association of SARS-CoV-2 infection with new-onset type 1 diabetes among pediatric patients from 2020 to 2021. JAMA Netw Open 2022; 5(9): e2233014.

15.

Amin

Philips

Bertoni

, et al. Differences in functional and survival outcomes between patients receiving primary surgery vs chemoradiation therapy for treatment of T1-T2 oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2023; 149(11): 980–986.

16.

Briggs

Hill

. Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States. Mult Scler 2020; 26(14): 1948–1952.

17.

Palchuk

London

Perez-Rey

, et al. A global federated real-world data and analytics platform for research. JAMIA Open 2023; 6(2): ooad035.

18.

Flanagan

Kaufmann

Krecke

, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79(3): 437–447.

19.

Oliveira

MCB

de Brito

Simabukuro

. Central nervous system demyelination associated with immune checkpoint inhibitors: Review of the literature. Front Neurol 2020; 11: 538695.

20.

U.S. Census Bureau, 2022, https://www2.census.gov/programs-surveys/popest/technical-documentation/file-layouts/2020-2021/NC-EST2021-ALLDATA.pdf

21.

Wingerchuk

Weinshenker

. Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. Mult Scler 2017; 23(2): 182–184.

22.

Cabrera-Gómez

Kurtzke

González-Quevedo

, et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009; 256(1): 35–44.

23.

Mealy

Wingerchuk

Greenberg

, et al. Epidemiology of neuromyelitis optica in the United States: A multicenter analysis. Arch Neurol 2012; 69(9): 1176–1180.

24.

Goodin

Oksenberg

Douillard

, et al. Genetic susceptibility to multiple sclerosis in African Americans. PLoS ONE 2021; 16(8): e0254945.

25.

Chi

Shao

Rhead

, et al. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet 2019; 15(1): e1007808.

26.

Viswanathan

Wah

. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. Mult Scler 2019; 25(11): 1452–1461.

27.

Pandit

Kundapur

. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014; 20(12): 1651–1653.

28.

Tisavipat

Jitpratoom

Siritho

, et al. The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: A population-based study. Mult Scler Relat Disord 2023; 70: 104511.

29.

Houzen

Kondo

Niino

, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology 2017; 89(19): 1995–2001.

30.

Langer-Gould

Gonzales

Smith

, et al. Racial and ethnic disparities in multiple sclerosis prevalence. Neurology 2022; 98(18): e1818–e1827.

31.

Cheong

Mohan

Warren

, et al. Multiple sclerosis in the Asia Pacific region: A systematic review of a neglected neurological disease. Front Neurol 2018; 9: 432.

32.

Kim

Mealy

Levy

, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology 2018; 91(22): e2089–e2099.

33.

Kim

Lee

, et al. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord 2017; 10(7): 265–289.

34.

Marignier

Hacohen

Cobo-Calvo

, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021; 20(9): 762–772.

35.

Klinger

Carlini

Gonzalez

, et al. Accuracy of race, ethnicity, and language preference in an electronic health record. J Gen Intern Med 2015; 30(6): 719–723.

36.

Polubriaginof

FCG

Ryan

Salmasian

, et al. Challenges with quality of race and ethnicity data in observational databases. J Am Med Inform Assoc 2019; 26(8–9): 730–736.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB